Rivaroxaban Does Not Reduce VTE Incidence in High-Risk Cancer Patients
THURSDAY, Feb. 21, 2019 -- In high-risk ambulatory patients with cancer, the incidence of venous thromboembolism or death due to venous thromboembolism during 180 days is not significantly reduced for rivaroxaban compared with placebo, according to... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 21, 2019 Category: Pharmaceuticals Source Type: news

Hormone Therapy Linked to CV Risk During Gender Transition Hormone Therapy Linked to CV Risk During Gender Transition
Transgender hormone therapy is associated with an increased risk for MI, stroke, and venous thromboembolism, underscoring the importance of patient counseling and close monitoring in this population.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 20, 2019 Category: Consumer Health News Tags: Cardiology News Source Type: news

CASSINI Trial publishes data on preventing blood clots in cancer patients
(Fred Hutchinson Cancer Research Center) The first clinical study investigating the use of the direct oral anticoagulant, rivaroxaban, to prevent blood clots in patients with cancer at high-risk published today in the New England Journal of Medicine. The study found no significant reduction in venous thromboembolism or death in the overall 180-day trial period; however, the researchers did observe a lower incidence of these events while patients were actively on the study drug, or during the on-treatment period. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 20, 2019 Category: Cancer & Oncology Source Type: news

Hancock Jaffe launches first-in-human VenoValve study
Hancock Jaffe Laboratories (NSDQ:HJLI) said today that it launched the first-in-human study of its VenoValve device, touting its successful implantation in the first subject in the study. The VenoValve is a porcine valve designed to be implanted into the femoral or popliteal vein to treat lower limb chronic venous insufficiency from damage to leg vein valves after deep vein thrombosis, the Irvine, Calif.-based company said. Hancock Jaffe said that the first patient in the Bogota, Colombia-based trial was walking a day after surgery and that the VenoValve appears to “be functioning as it should” w...
Source: Mass Device - February 19, 2019 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Featured Vascular hancockjaffelabs Source Type: news

PET/CT imaging agent shows promise for better diagnosis of acute venous thromboembolism
(Society of Nuclear Medicine and Molecular Imaging) Researchers report that a new nuclear medicine tracer may allow better diagnosis of acute venous thromboembolism (VTE). Acute VTE is a disease that includes deep-vein thrombosis and its complication, pulmonary embolism, which can be fatal. The research is featured in the February issue of The Journal of Nuclear Medicine. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 15, 2019 Category: International Medicine & Public Health Source Type: news

VTE Risk High in Spine Disease
(MedPage Today) -- More deep venous thrombosis than pulmonary embolism seen in ankylosing spondylitis (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - February 14, 2019 Category: Rheumatology Source Type: news

Platelet doppelg ä ngers tackle thrombosis and cancer metastasis
(American Association for the Advancement of Science) Anne-Laure Papa and colleagues have created decoys of platelets -- the body's clot-forming blood cells -- that prevented the formation of dangerous blood clots in vessels (or thrombosis) and combated cancer metastasis in preclinical models. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 13, 2019 Category: Cancer & Oncology Source Type: news

Risk of Thrombosis Over 2-Fold Higher in Male Breast Cancer With Tamoxifen (CME/CE)
(MedPage Today) -- Increased rate for men consistent with that found in women -- maybe higher (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - February 12, 2019 Category: Cardiology Source Type: news

Treatment Not Needed for DVT in Very Advanced Cancer Patients Treatment Not Needed for DVT in Very Advanced Cancer Patients
Deep vein thrombosis (DVT) is seen in about a third of patients with very advanced cancer, but its presence is not associated with significant symptoms or survival.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 12, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Medical News Today: What to know about a blood clot behind the knee
A blood clot can form behind the knee due to injuries, surgery, or poor blood flow. A clot forming in a leg vein is a serious condition that can lead to potentially life-threatening complications, such as a pulmonary embolism. Learn more here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 8, 2019 Category: Consumer Health News Tags: Venous Thromboembolism (VTE) Source Type: news

Thoratec inks $12m investor suit settlement deal
Abbott (NYSE:ABT) owned Thoratec is seeking approval for a $11.9 million deal to settle class action claims that it and some of its officers hid facts about its Heartmate II heart pump’s thrombosis rate that would have negatively affected share prices, according to recently released court documents. Investor Bradley Cooper originally brought the suit against the company in January 2014, on behalf of anyone who bought stock between April 29, 2010, and Nov. 27, 2013. Plaintiffs in the case argued that the company failed to warn investors about a blood clot problem with its HeartMate II implant implicated in a...
Source: Mass Device - February 6, 2019 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Cardiac Assist Devices Cardiovascular Legal News Abbott Thoratec Corp. Source Type: news

Thrombosis a Risk With Tamoxifen in Male Breast Cancer
(MedPage Today) -- Data consistent with findings in women (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - February 6, 2019 Category: Cardiology Source Type: news

Estrogen and Venous Thrombosis: Route, Type, and Dose Matter! Estrogen and Venous Thrombosis: Route, Type, and Dose Matter!
JoAnn Manson reviews a large study that provides evidence about the safety of different estrogen formulations for menopausal hormone therapy.Medscape Ob/Gyn (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 1, 2019 Category: Consumer Health News Tags: Ob/Gyn & Women ' s Health Commentary Source Type: news

Products made from whole milk, not 2% "processed" milk, reduce risk of blood clots in the brain
(Natural News) A study published in the European Journal of Epidemiology reveals that soured whole milk products are more effective at reducing the risk of suffering from brain thrombosis or ischemic stroke compared with other dairy products — such as low-fat soured milk products and cheese, buttermilk, or milk — with varying fat percentages. A team of researchers at... (Source: NaturalNews.com)
Source: NaturalNews.com - January 27, 2019 Category: Consumer Health News Source Type: news

Endologix ’s CE Mark for Nellix is Suspended
It looks like more bad news for Endologix.  The Irvine, CA-based company said its CE Mark for the Nellix EndoVascular Aneurysm Sealing System has been suspended by its Notified Body, GMED. Endologix first received approval in Europe for the device in 2013. The Nellix system was developed as an alternative treatment to traditional endovascular aneurysm repair for an abdominal aortic aneurysm. The system is designed to seal an entire aneurysm. “The notification from GMED is a regulatory action and is not in response to any new information beyond our recent FSN,” Dr. Matt Thomps...
Source: MDDI - January 25, 2019 Category: Medical Devices Authors: Omar Ford Tags: Cardiovascular Regulatory and Compliance Source Type: news

New SCCT Guidelines Reflect Expanding Role for CT in TAVR New SCCT Guidelines Reflect Expanding Role for CT in TAVR
It features nuts-and-bolts recommendations, including those for specific scanners, but also thorny issues like leaflet thrombosis and valve-in-valve procedures for failed bioprosthesis.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 18, 2019 Category: Consumer Health News Tags: Cardiology News Source Type: news

Aspiration Thrombectomy in STEMI PCI Plummets Nationwide Aspiration Thrombectomy in STEMI PCI Plummets Nationwide
No benefits were found for thrombus aspiration, either routine or selective, but there remains an unmet need in high-risk patients undergoing PCI.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 16, 2019 Category: Consumer Health News Tags: Cardiology News Source Type: news

What Are Potential Complications of Large for Gestational Birthweight?
Discussion Infant size at birth is determined mainly by genetics, but also pregnancy and environmental factors. Large for gestational age (LGA) is defined as a mean weight> 2 standard deviations above the weight for gestational age or above the 90th percentile on growth charts (or ~4000 g on WHO growth charts). Macrosomia is a term used for a term infant who is> 4000g. Risk factors for LGA infants includes: Male infant Maternal Genetic disposition Hispanic ethnicity Diabetic Multiparity or grand parity Obesity History of previous LGA infant Prenatal ultrasound is very helpful for antenatal management. First tri...
Source: PediatricEducation.org - January 14, 2019 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

A 55-Year-Old Woman Short of Breath: USMLE Question A 55-Year-Old Woman Short of Breath: USMLE Question
A 55-year-old woman presents with shortness of breath. She has a history of deep vein thrombosis and current breast cancer. What's the next step in management?Osmosis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 11, 2019 Category: Consumer Health News Tags: Med Students Interactive Quiz Source Type: news

Oral HRT for Menopause Has Highest VTE Risk, Dermal Route Safest Oral HRT for Menopause Has Highest VTE Risk, Dermal Route Safest
Women taking HRT for menopausal symptoms should be counseled to use transdermal preparations over oral ones to reduce their venous thromboembolism risk, conclude UK experts following large study.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 10, 2019 Category: Consumer Health News Tags: Ob/Gyn & Women ' s Health News Source Type: news

Oral HRT for Menopause Has Highest VTE Risk, Patches Safest Oral HRT for Menopause Has Highest VTE Risk, Patches Safest
Women taking HRT for menopausal symptoms should be counseled to use transdermal preparations over oral ones to reduce their venous thromboembolism risk, conclude UK experts following large study.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 10, 2019 Category: Consumer Health News Tags: Ob/Gyn & Women ' s Health News Source Type: news

Transdermal HRT Not Linked to Increased Risk for VTE
THURSDAY, Jan. 10, 2019 -- Oral hormone replacement therapy (HRT) is associated with an increased risk for venous thromboembolism (VTE), while transdermal preparations are not linked to increased risk, according to a study published online Jan. 9 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 10, 2019 Category: Pharmaceuticals Source Type: news

Hancock Jaffe sets endpoints for FIH VenoValve study
Hancock Jaffe Laboratories (NSDQ:HJLI) today announced the endpoints for its planned first-in-human study of its VenoValve device. The VenoValve is a porcine valve designed to be implanted into the femoral or popliteal vein to treat lower limb chronic venous insufficiency from damage to leg vein valves after deep vein thrombosis, the Irvine, Calif.-based company said. Endpoints for the study include improvements in reflux time measured by duplex scans and rVCSS, VAS and VEINES scores, which are used as clinical measurements for venous disease. Hancock Jaffe said that patients in the trial will be monitored at reg...
Source: Mass Device - January 9, 2019 Category: Medical Devices Authors: Fink Densford Tags: Cardiovascular Clinical Trials Replacement Heart Valves hancockjaffelabs Source Type: news

Medtech veteran Reggie Groves on leading with ‘patients first’
In guiding Medtronic through the Fidelis lead recall, medtech veteran Reggie Groves always took a “patients first” perspective. At DeviceTalks West 2018, Groves explained how her time at Medtronic influenced her as a leader and how she has brought those lessons into her role as CEO of Reva Medical. Once the world’s most popular defibrillator lead, Medtronic’s Fidelis leads were in hundreds of thousands of patients in the U.S. So when the device began delivering random, painful shocks to people about a decade ago, Medtronic officials were worried. That included Reggie Groves, who was charged with run...
Source: Mass Device - January 7, 2019 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Featured Recalls Vascular Wall Street Beat DeviceTalks West Medtronic Reva Medical Inc. Source Type: news

Endologix Voluntarily Recalls Nellix
Endologix said it was initiating a voluntary recall of the existing inventory of its Nellix endovascular aneurysm sealing system. The Irvine, CA-based company said it was limiting the device to only be available for use under clinical protocol with pre-screened patients that adhere to the current indications. Endologix said it was taking these steps in order to ensure optimal outcomes for patients. This decision is one of several actions taken by Endologix following a new management mandate in August 2018 to ensure the most appropriate use of each of its devices and is in alignment with a recent publication by the European...
Source: MDDI - January 6, 2019 Category: Medical Devices Authors: Omar Ford Tags: Cardiovascular Regulatory and Compliance Source Type: news

New DVT Device Designed to Tackle Stubborn ‘Wall-to-Wall’ Clot
Vetex Medical recently completed the first-in-man case in a multicenter study of a new deep vein thrombosis (DVT) device that has the potential to reduce hospital stays and costs associated with DVT treatment. The Galway, Ireland-based company said the Vetex Thrombectomy Catheter is the first device to combine rotational and grasping action to quickly and gently remove large volumes of stubborn wall-adherent clot in a single session, without thrombolytic drugs. The first patient was treated by the study’s principal investigator Stephen Black, MD, Narayan Thulasidasan, MD, and their team at Guyâ€...
Source: MDDI - January 4, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: R & D Source Type: news

People leaving hospital after medical illness do not benefit from extended clot reducing treatment
Taking rivaroxaban after discharge from hospital does not significantly reduce the risk of venous thromboembolism, either blood clots in large veins or of dying from clots travelling to the lungs. This large multinational trial sought to find out whether using the anticoagulant rivaroxaban for 45 days after discharge was effective. Continued use offered a very small reduction in the risk of a venous thromboembolism, but also slightly increased the risk of major bleeding. Neither result reached statistical significance. The trial was terminated because of the lower than expected number of clots. (Source: Current Awareness S...
Source: Current Awareness Service for Health (CASH) - January 3, 2019 Category: Consumer Health News Source Type: news

Cities really are death traps: Sitting in traffic found to suppress HDL "good" cholesterol that prevents cardiovascular disease
(Natural News) Traffic-related air pollution is seen to manipulate the levels of high-density lipoprotein (HDL), otherwise known as “good” cholesterol. These are the findings of the American Heart Association (AHA) in their recent study published in Arteriosclerosis, Thrombosis, and Vascular Biology. These lowered levels are evident even after brief and medium-length exposures to air pollution.... (Source: NaturalNews.com)
Source: NaturalNews.com - December 28, 2018 Category: Consumer Health News Source Type: news

ASH Develops Practice Guidelines for Venous Thromboembolism
Clinical practice guidelines presented for diagnosis, treatment, pediatric and pregnancy - linked VTE (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 27, 2018 Category: Cancer & Oncology Tags: Cardiology, Gynecology, Internal Medicine, Critical Care, Oncology, Pediatrics, Pharmacy, Surgery, Geriatrics, Journal, Source Type: news

MI, Stroke Risks Rise Months Before Cancer Diagnosis MI, Stroke Risks Rise Months Before Cancer Diagnosis
About 5 months before a cancer diagnosis, the risk for arterial thromboembolism increases and continues to climb as the diagnosis date draws closer.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - December 27, 2018 Category: Cardiology Tags: Hematology-Oncology News Source Type: news

ASH Develops Practice Guidelines for Venous Thromboembolism
THURSDAY, Dec. 27, 2018 -- The American Society of Hematology (ASH) has developed new guidelines for the treatment of venous thromboembolism (VTE); the clinical practice guidelines were recently published in Blood Advances. The guidelines address... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 27, 2018 Category: Pharmaceuticals Source Type: news

MI, Stroke Risk Elevates Months Before Cancer Diagnosis MI, Stroke Risk Elevates Months Before Cancer Diagnosis
About 5 months before a cancer diagnosis, the risk for arterial thromboembolism increases and continues to climb as the diagnosis date draws closer.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 26, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Vetex Medical launches first-in-human thrombectomy cath trial
Vascular device developer Vetex Medical said today that it launched a first-in-human trial of its Vetex thrombectomy catheter intended for treating deep vein thrombosis and that the first patient in the trial has been treated in the study. The Galway, Ireland-based company said that the Vetex cath uses both rotational and grasping action during the removal of clots, and that the device can handle large volumes and wall-adherent clots without the need for thrombolytic drugs. The first patient in the trial was treated by the study principal investigator Dr. Stephen Black and Dr. Narayan Thulasidasan at London’s St. Tho...
Source: Mass Device - December 18, 2018 Category: Medical Devices Authors: Fink Densford Tags: Blood Management Clinical Trials Vascular vetexmedical Source Type: news

Colombia clears Hancock Jaffe first-in-human VenoValve trial
Hancock Jaffe Laboratories (NSDQ:HJLI) said today that it won regulatory approval from Colombia’s INVIMA, the country’s FDA equivalent, to launch a first-in-human trial of its VenoValve device. The VenoValve is a porcine valve designed to be implanted into the femoral or popliteal vein to treat lower limb chronic venous insufficiency from damage to leg vein valves after deep vein thrombosis, the Irvine, Calif.-based company said. Hancock Jaffe said it is now making arrangements to export VenoValves into Colombia, as well as to begin screening and enrollment of patients in the study. The company said i...
Source: Mass Device - December 17, 2018 Category: Medical Devices Authors: Fink Densford Tags: Cardiovascular Clinical Trials Featured Replacement Heart Valves hancockjaffelabs Source Type: news

A guide to preventing blood clots on long flights
(Natural News) Air travel is convenient, but it’s a technological advancement that’s also linked to some fatal health conditions. For example, frequent flyers are at risk of developing blood clots, especially when a plane trip takes longer than four hours. What is deep vein thrombosis (DVT)? The condition called deep vein thrombosis (DVT) occurs when... (Source: NaturalNews.com)
Source: NaturalNews.com - December 16, 2018 Category: Consumer Health News Source Type: news

Apixaban Prevents VTE in Cancer Patients Initiating Chemotherapy
FRIDAY, Dec. 14, 2018 -- Among patients with cancer starting chemotherapy who are at intermediate-to-high risk, rates of venous thromboembolism are significantly lower for thromboprophylaxis with apixaban versus placebo, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 14, 2018 Category: Pharmaceuticals Source Type: news

Janssen Submits Supplemental New Drug Application (sNDA) to FDA for XARELTO ® (rivaroxaban) to Prevent Venous Thromboembolism (VTE) in Acute Medically Ill Patients
(Source: Johnson and Johnson)
Source: Johnson and Johnson - December 14, 2018 Category: Pharmaceuticals Source Type: news

Apixaban Significantly Reduces VTE in Cancer Patients Apixaban Significantly Reduces VTE in Cancer Patients
Cancer patients at risk for venous thromboembolism significantly benefited from apixaban compared with placebo. But routine primary thromboprophylaxis is not yet recommended.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 11, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

J & J ’s Cerenovus launches global thrombectomy registry
Johnson & Johnson‘s (NYSE:JNJ) Cerenovus said today that it launched a new registry aiming to collect and analyze stroke-inducing blood clots removed with the company’s Embotrap II revascularization device. The Irvine, Calif.-based company touted the Excellent registry as the single largest global registry of its kind to date, looking to enroll up to 1,000 ischemic stroke patients across 50 locations in the U.S. and Europe. Investigators in the trial will collect and analyze clots removed to explore how different characteristics, including size, composition and density may affect outcomes, the com...
Source: Mass Device - December 10, 2018 Category: Medical Devices Authors: Fink Densford Tags: Blood Management Clinical Trials Featured Neurological cerenovus johnsonandjohnson Source Type: news

AHA Scientific Statement: Low Risk of Side Effects for Statins
MONDAY, Dec. 10, 2018 -- Statins are associated with a low risk for side effects, according to a scientific statement from the American Heart Association (AHA) published online Dec. 10 in Arteriosclerosis, Thrombosis and Vascular Biology. Connie B.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 10, 2018 Category: Pharmaceuticals Source Type: news

ASH: Rivaroxaban Prevents Blood Clots in At-Risk Cancer Patients
WEDNESDAY, Dec. 5, 2018 -- Rivaroxaban can prevent venous thromboembolism (VTE) in cancer patients at increased risk, according to a study presented at the annual meeting of the American Society of Hematology, held from Dec. 1 to 4 in San... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 5, 2018 Category: Pharmaceuticals Source Type: news

Cerebral Venous Sinus Thrombosis Misdiagnosed As Migraine Cerebral Venous Sinus Thrombosis Misdiagnosed As Migraine
A misdiagnosis of cerebral venous thrombosis resulted in a catastrophic outcome for this patient. What were the potentially avoidable pitfalls in this case?Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 5, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news

' Marginal Benefit' With Rivaroxaban in Cancer Patients'Marginal Benefit' With Rivaroxaban in Cancer Patients
The oral drug rivaroxaban was used for prophylaxis against primary venous thromboembolism in ambulatory cancer patients treated in the outpatient setting.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 4, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

New Phase 3 CASSINI Data Presented on the Use of XARELTO ® (rivaroxaban) for Venous Thromboembolism (VTE) Prevention in High-Risk Cancer Patients
(Source: Johnson and Johnson)
Source: Johnson and Johnson - December 4, 2018 Category: Pharmaceuticals Source Type: news

Inflammation, VTE, and What We Can Do About It Inflammation, VTE, and What We Can Do About It
A new study examines the association between venous thromboembolism and three chronic inflammatory diseases. How might anti-inflammatory treatments impact the risk of VTE in these patients?European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 4, 2018 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Drug dramatically reduces risk of dangerous blood clots in cancer patients
(The Ottawa Hospital) A large clinical trial published in the New England Journal of Medicine provides the first approach for safely preventing blood clots (venous thromboembolism) in people with cancer. Venous thromboembolism is the second leading cause of death in cancer patients and it can also affect quality of life. About half of people newly diagnosed with a solid cancer could be candidates for the strategy, which involves a low dose of a direct oral anticoagulant called apixaban. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 4, 2018 Category: Cancer & Oncology Source Type: news

Cleveland Clinic-led study: Rivaroxaban reduced blood clots and related death in cancer patients
(Cleveland Clinic) Cleveland Clinic medical oncologist and researcher, Alok Khorana, M.D., is the primary investigator on a study that concluded rivaroxaban for venous thromboembolism (VTE), a blood clot in the venous system, significantly reduced VTE and VTE-related death for outpatient, at-risk cancer patients while they were taking the oral blood thinner. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 4, 2018 Category: Cancer & Oncology Source Type: news

Risk of VTE During and After Hospitalization in IBD Patients Risk of VTE During and After Hospitalization in IBD Patients
Venous thromboembolism is a recognized complication of inflammatory bowel diseases. When are IBD patients at most risk of thromboembolic events?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 29, 2018 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

ECG Educational Standards for Prehospital Providers
The level of knowledge pertaining to electrocardiogram (ECG) interpretation among prehospital healthcare providers undoubtedly impacts patient outcomes. EMS personnel from EMRs to EMTs, AEMTs and paramedics play a critical role in the care of acutely ill and injured patients. First responders make critical decisions regarding initial assessment, intervention and transport. They must do so expeditiously. Such decisions have profound implications on quality and continuity of care. The importance of such actions becomes especially evident in regard to on-scene ECG interpretation. The prehospital providers' ECG interpretation ...
Source: JEMS Patient Care - November 27, 2018 Category: Emergency Medicine Authors: Jonathan Barney, BA, EMT, MS3 Tags: Training Exclusive Articles Cardiac & Resuscitation Source Type: news

ECG Educational Standards for Prehospital Providers
Conclusion As the role of evidence-based medicine becomes more prominent in the field of emergency medicine, a clear view of the current state of ECG education and platform from which to implement uniform standards becomes increasingly essential; especially as research expands into the prehospital setting. Further research into EMS education may identify both strengths and weaknesses in basic ECG interpretation appropriate for first responders. Implementing minimum ECG interpretation standards for EMS personnel nationwide is one potential option to ensure prehospital educational institutions stay responsive to current scie...
Source: JEMS Special Topics - November 27, 2018 Category: Emergency Medicine Authors: Jonathan Barney, BA, EMT, MS3 Tags: Training Exclusive Articles Cardiac & Resuscitation Source Type: news